CareDx Partners with TC BioPharm to Advance Hematology Oncology Research and Treatments

### CareDx Partners with TC BioPharm to Enhance Hematology Oncology Research

CareDx, Inc., a prominent precision medicine company based in Brisbane, California, has announced a strategic partnership with TC BioPharm to leverage its AlloCell™ solution in the ongoing ACHIEVE clinical trial. This collaboration marks a significant advancement in the company's commitment to hematology oncology, as it focuses on pharmacokinetic analysis for TCB008, an allogeneic gamma-delta T-cell therapy. The ACHIEVE trial is a phase II, adaptive, open-label study designed to evaluate the efficacy and effectiveness of TCB008 in patients diagnosed with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS). By utilizing AlloCell, CareDx aims to enhance the understanding of TCB008's therapeutic potential and its role in reconstituting the immune system of patients undergoing cell therapy.

The AlloCell solution has a proven track record, having been employed in ten prior clinical trials, and it will now be utilized in four active studies, including ACHIEVE. Marica Grskovic, PhD, Chief Strategy Officer at CareDx, highlights this partnership as a strategic alignment with the company's growth strategy, allowing for comprehensive pharmacokinetic monitoring. This is particularly crucial for understanding how TCB008 behaves in the body, including its expansion and persistence, which are vital for assessing the treatment’s effectiveness on AML patients. Grskovic's enthusiasm for this collaboration underscores CareDx's focus on advancing innovative therapies in the oncology landscape.

Alison Bracchi, Executive Vice President of Clinical Operations at TC BioPharm, also emphasizes the importance of this partnership in driving the development of TCB008 for blood cancers. The AlloCell test's role in evaluating the therapy's impact on the immune system of trial participants is crucial for determining the duration and effectiveness of the gamma-delta T-cells. This collaborative effort not only represents a significant step forward in the treatment of challenging hematological conditions but also reinforces CareDx's dedication to delivering high-value healthcare solutions and genomics-based information tailored to transplant patients.

In addition to its partnership with TC BioPharm, CareDx continues to solidify its position as a leader in the precision medicine space. The company is committed to providing innovative healthcare solutions for transplant patients and caregivers, enhancing their quality of care through advanced genomic testing and analytics. This latest initiative showcases CareDx's proactive approach to improving treatment outcomes for patients battling complex diseases like AML and MDS.

As CareDx collaborates with TC BioPharm, the partnership signifies a forward-thinking strategy that could pave the way for new therapeutic options in hematology oncology. The integration of AlloCell in clinical trials not only enhances research capabilities but also reinforces CareDx's commitment to improving patient care and outcomes in the field of blood cancers. For more details on their services and innovations, visit www.caredx.com.